Weibull prediction of event times in clinical trials

Pharmaceutical Statistics

Volumn 7, Issue 2, 2008, Pages 107-120

  Ying, Gui Shuang ^a   Heitjan, Daniel F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Interim analysis; Predictie power; Time to event

Indexed keywords

GAMMA INTERFERON; PLACEBO;

ARTICLE; BAYES THEOREM; CALIBRATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOTHERAPY; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MONTE CARLO METHOD; MULTICENTER STUDY; NONPARAMETRIC TEST; PARAMETRIC TEST; PREDICTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL; SURVIVAL RATE; WEIBULL SURVIVAL MODEL; ALGORITHM; COMPUTER SIMULATION; METHODOLOGY;

ALGORITHMS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; RESEARCH DESIGN;

EID: 46449103064     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.271     Document Type: Article

References (27)

1. Bagiella E, Heitjan DF. Predicting analysis times in randomized clinical trials. Statistics in Medicine 2001; 20:2055-2063.
2. Ying GS, Heitjan DF, Chen TT. Nonparametric prediction of event times in randomized clinical trials. Clinical Trials 2004; 1:352-361.
3. Abrams K, Ashby D, Errington D. A Bayesian approach to Weibull survival models - application to a cancer clinical trial. Lifetime Data Analysis 1996; 2:159-174.
4. Carroll KJ. On the use and utility of the Weibull model in analysis of survival data. Controlled Clinical Trials 2003; 24:682-701.
5. Dellaportas P, Wright D. Numerical prediction for the two-parameter Weibull distribution. The Statistician 1991; 40:365-372.
6. Evans IG, Nigm AM. Bayesian prediction for two-parameter Weibull lifetime models. Communications in Statistics - Theory and Methods 1980; A9(6): 649-658.
7. Lecoutre B, Mabika B, Derzko J. Assessment and monitoring in clinical trials when survival curves have distinct shape: a Bayesian approach with Weibull modelling. Statistics in Medicine 2002; 21: 663-674.
8. Mee RW, Kushary D. Prediction limits for the Weibull distribution utilizing simulation. Computational Statistics & Data Analysis 1994; 17:327-336.
9. Nelson W. Weibull prediction of a future number of failures. Quality and Reliability Engineering International 2000; 16:23-26.
10. Qian J, Stangl DK, George S. A Weibull model for survival data: using prediction to decide when to stop a clinical trial. In Bayesian biostatistics, Berry DA, Stangl DK (eds). Marcel Dekker: New York, 1996.
11. Tierney L, Kass RE, Kadane JB. Fully exponential Laplace approximation of expectations and variances of non-positive functions. Journal of the American Statistical Association 1989; 84: 710-716.
12. Naylor JC, Smith FM. Application of a method for the efficient computation of posterior distributions. Applied Statistics 1982; 31:214-225.
13. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis (2nd edn). Chapman & Hall/CRC: London, Boca Raton, FL, 2003.
14. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 1991; 324:509-516.
15. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. Wiley: New York, 1991.
16. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Controlled Clinical Trials 1986; 7:8-17.
17. Balasooriya U, Abeysinghe T. Selecting between gamma and Weibull distribution - an approach based on predictions of order statistics. Journal of Applied Statistics 1994; 21:17-27.
18. Klein JP, Moeschberger ML. The robustness of several estimators of the survivorship function with randomly censored data. Communications in Statistics - Simulation and Computation 1989; 18: 1087-1112.
19. Miller RG. What price Kaplan-Meier? Biometrics 1983; 39:1077-1081.
20. Meier P, Karrison T, Chappell R, Xie H. The price of Kaplan-Meier. Journal of the American Statistical Association 2004; 99:890-896.
21. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, for the REMATCH Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. The New England Journal of Medicine 2001; 345:1435-1443.
22. Donovan JM, Elliott MR, Heitjan DF. Predicting event times in clinical trials when treatment arm is masked. Journal of Biopharmaceutical Statistics 2006; 16:343-356.
23. Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of a continued observation. Journal of Chronic Diseases 1981; 34:469-479.
24. Schoenfeld DA. Sample size formula for the proportional-hazards regression model. Biometrics 1983; 8:1191-1198.
25. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance and stratification. Biometrics 1986; 42:507-519.
26. Yateman NA, Skene AM. Sample size for proportional hazards survival studies with arbitrary patient entry and loss to follow-up distributions. Statistics in Medicine 1992; 12:1103-1113.
27. Yateman NA, Skene AM. The use of simulation in the design of two cardiovascular survival studies. Statistics in Medicine 1993; 12:1365-1372.